Skip to content

Author

Zai-Jue Zheng

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-1301, an oral PCSK9 inhibitor, in healthy participants: a first-in-human, randomized, double-blind, placebo-controlled phase I trial

Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) is a proven therapeutic strategy for reducing plasma low density lipoprotein-cholesterol (LDL-C). HRS-1301 is an oral small molecule PCSK9 inhibitor designed to prevent LDL receptor degradation, representing a novel therapeutic approach for dysli...

Shi-Long Zhong, X. Wang, P. Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.